Alector (ALEC) Competitors $2.26 +0.07 (+2.95%) Closing price 03:59 PM EasternExtended Trading$2.28 +0.01 (+0.44%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ALEC vs. CRON, IMNM, QURE, PGEN, AKBA, AVXL, NRIX, NAGE, PHAR, and AVBPShould you be buying Alector stock or one of its competitors? The main competitors of Alector include Cronos Group (CRON), Immunome (IMNM), uniQure (QURE), Precigen (PGEN), Akebia Therapeutics (AKBA), Anavex Life Sciences (AVXL), Nurix Therapeutics (NRIX), Niagen Bioscience (NAGE), Pharming Group (PHAR), and ArriVent BioPharma (AVBP). These companies are all part of the "pharmaceutical products" industry. Alector vs. Its Competitors Cronos Group Immunome uniQure Precigen Akebia Therapeutics Anavex Life Sciences Nurix Therapeutics Niagen Bioscience Pharming Group ArriVent BioPharma Alector (NASDAQ:ALEC) and Cronos Group (NASDAQ:CRON) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation, risk and media sentiment. Which has more volatility and risk, ALEC or CRON? Alector has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500. Comparatively, Cronos Group has a beta of 1.01, meaning that its share price is 1% more volatile than the S&P 500. Does the media prefer ALEC or CRON? In the previous week, Cronos Group had 1 more articles in the media than Alector. MarketBeat recorded 2 mentions for Cronos Group and 1 mentions for Alector. Cronos Group's average media sentiment score of 0.82 beat Alector's score of 0.00 indicating that Cronos Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alector 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cronos Group 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer ALEC or CRON? Alector currently has a consensus target price of $4.17, indicating a potential upside of 83.96%. Given Alector's stronger consensus rating and higher possible upside, analysts plainly believe Alector is more favorable than Cronos Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alector 2 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.29Cronos Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has higher valuation and earnings, ALEC or CRON? Cronos Group has higher revenue and earnings than Alector. Alector is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlector$100.56M2.28-$119.05M-$1.16-1.95Cronos Group$117.61M8.32$41.08M$0.0551.10 Do institutionals & insiders believe in ALEC or CRON? 85.8% of Alector shares are owned by institutional investors. Comparatively, 8.7% of Cronos Group shares are owned by institutional investors. 9.7% of Alector shares are owned by company insiders. Comparatively, 7.3% of Cronos Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Is ALEC or CRON more profitable? Cronos Group has a net margin of 14.19% compared to Alector's net margin of -142.10%. Cronos Group's return on equity of -3.78% beat Alector's return on equity.Company Net Margins Return on Equity Return on Assets Alector-142.10% -112.06% -26.37% Cronos Group 14.19%-3.78%-3.62% SummaryCronos Group beats Alector on 11 of the 16 factors compared between the two stocks. Get Alector News Delivered to You Automatically Sign up to receive the latest news and ratings for ALEC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALEC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALEC vs. The Competition Export to ExcelMetricAlectorMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$229.24M$3.11B$5.74B$9.56BDividend YieldN/A2.23%4.53%4.07%P/E Ratio-1.9520.3730.4325.14Price / Sales2.28238.33392.4187.63Price / CashN/A42.3737.0358.50Price / Book3.247.918.956.21Net Income-$119.05M-$54.72M$3.26B$265.38M7 Day Performance-7.93%1.58%1.03%-1.12%1 Month Performance39.81%5.81%4.28%-0.68%1 Year Performance-57.18%8.71%28.38%18.92% Alector Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALECAlector3.6161 of 5 stars$2.27+3.0%$4.17+84.0%-57.8%$229.24M$100.56M-1.95270CRONCronos Group0.9408 of 5 stars$2.37-6.0%N/A+2.5%$909.63M$117.61M47.40450IMNMImmunome1.8463 of 5 stars$10.28+3.4%$23.14+125.1%-37.1%$894.77M$9.04M-3.3440QUREuniQure2.8388 of 5 stars$16.18+2.5%$37.45+131.5%+128.3%$887.80M$27.12M-4.13500Analyst RevisionPGENPrecigen3.8662 of 5 stars$2.94+58.9%$6.00+104.1%+184.1%$876.03M$3.92M-7.00190Trending NewsAnalyst ForecastOptions VolumeAnalyst RevisionHigh Trading VolumeAKBAAkebia Therapeutics4.0065 of 5 stars$3.25-1.2%$6.75+107.7%+116.7%$861.71M$160.18M-19.12430AVXLAnavex Life Sciences3.7265 of 5 stars$9.94-1.7%$44.00+342.7%+57.9%$853.75MN/A-17.4440NRIXNurix Therapeutics2.398 of 5 stars$10.58+0.2%$28.87+172.8%-60.1%$808.84M$54.55M-4.05300Positive NewsNAGENiagen Bioscience1.3448 of 5 stars$10.02+3.2%$13.42+33.9%N/A$799.10M$99.60M47.72120PHARPharming Group1.9805 of 5 stars$11.65+2.4%$30.00+157.5%+56.3%$798.14M$297.20M-89.62280Gap UpAVBPArriVent BioPharma2.4321 of 5 stars$19.53+4.9%$39.14+100.4%-20.4%$792.33MN/A-4.8640Analyst Upgrade Related Companies and Tools Related Companies Cronos Group Alternatives Immunome Alternatives uniQure Alternatives Precigen Alternatives Akebia Therapeutics Alternatives Anavex Life Sciences Alternatives Nurix Therapeutics Alternatives Niagen Bioscience Alternatives Pharming Group Alternatives ArriVent BioPharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALEC) was last updated on 8/21/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alector, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alector With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access